The Delhi High Court has stayed a Rs 151.2 crore recovery notice issued by the National Pharmaceutical Pricing Authority (NPPA) to AstraZeneca Pharma India. The dispute involves pricing allegations for the Symbicort Turbuhaler inhaler between 2016 and 2025. This legal relief remains in effect until the next hearing on January 11, 2027.
The Delhi High Court has provided temporary relief to AstraZeneca Pharma India by putting a stop to recovery actions initiated by the National Pharmaceutical Pricing Authority (NPPA). The regulator had demanded approximately Rs 151.2 crore, alleging that the company sold its Symbicort Turbuhaler inhalers at prices higher than the limits set under the Drugs (Prices Control) Order, 2013.
The company informed the stock exchanges on November 2, 2026, regarding the court order issued on October 29. The core of the disagreement is whether the specific version of the inhaler—the 160/4.5 formulation—falls under the government’s price control rules. AstraZeneca maintains that its product is exempt from these specific regulations, a claim that will be central to the upcoming legal proceedings.
This is the second major legal challenge regarding pricing for the company in recent months. In August 2026, the Delhi High Court had stayed another NPPA demand related to the company’s Betaloc-50 medication. In that instance, the court allowed the stay on the condition that the company deposits 15% of the demanded amount. Investors often monitor these disputes closely because they highlight the ongoing regulatory pressure on pharmaceutical pricing, which can create uncertainty around potential financial liabilities.
The Rs 151 crore demand represents a significant potential financial burden. While the court has paused the recovery action until January 11, 2027, the long-term impact on the company’s finances will depend on the final court ruling. If the court decides that the pricing did indeed violate the rules, the company could be required to pay the demand. If the court sides with the company’s interpretation regarding product classification, the risk is removed.
Shareholders and market observers will likely look for updates from the court proceedings scheduled for January. The outcome of this case could provide more clarity on how the company’s products are categorized for pricing purposes and whether there are further financial risks regarding other drugs in its portfolio.